title: Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009.
abstract: Asia has a disproportionately large share of the world's hepatocellular carcinoma (HCC), mainly because of the endemic status of chronic hepatitis B and C viruses, which leads to liver cirrhosis and an increased risk of HCC. This etiological factor presents important opportunities for prevention, early detection, diagnosis, and treatment of HCC. This consensus statement reviews the available medical evidence for management of HCC in Asia, and gives treatment recommendations that are adapted to resource availability in this diverse region with disparate health-care delivery systems.
authors.affiliation: National Cancer Centre, Singapore; Duke-NUS Graduate Medical School, Singapore. dmopyh@nccs.com.sg
authors.forename: Donald
authors.initials: D
authors.lastname: Poon
authors.forename: Benjamin O
authors.initials: BO
authors.lastname: Anderson
authors.forename: Li-Tzong
authors.initials: LT
authors.lastname: Chen
authors.forename: Koichi
authors.initials: K
authors.lastname: Tanaka
authors.forename: Wan Yee
authors.initials: WY
authors.lastname: Lau
authors.forename: Eric
authors.initials: E
authors.lastname: Van Cutsem
authors.forename: Harjit
authors.initials: H
authors.lastname: Singh
authors.forename: Wan Cheng
authors.initials: WC
authors.lastname: Chow
authors.forename: London Lucien
authors.initials: LL
authors.lastname: Ooi
authors.forename: Pierce
authors.initials: P
authors.lastname: Chow
authors.forename: Maung Win
authors.initials: MW
authors.lastname: Khin
authors.forename: Wen Hsin
authors.initials: WH
authors.lastname: Koo
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000627:therapeutic use; D001208:Asia / Q000453:epidemiology; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D017115:Catheter Ablation; D016461:Chemoembolization, Therapeutic; D017024:Chemotherapy, Adjuvant; D003226:Congresses as Topic; D003362:Cost-Benefit Analysis; D003906:Developing Countries / Q000191:economics; D013505:Digestive System Surgical Procedures / Q000191:economics; D016527:Drug Costs; D055088:Early Detection of Cancer; D019317:Evidence-Based Medicine; D019983:Guideline Adherence; D017048:Health Care Costs; D006297:Health Services Accessibility; D054625:Healthcare Disparities; D006498:Hepatectomy; D017325:Hepatitis B Vaccines / Q000627:therapeutic use; D019694:Hepatitis B, Chronic / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D006801:Humans; D008113:Liver Neoplasms / Q000175:diagnosis / Q000191:economics / Q000401:mortality / Q000517:prevention & control / Q000628:therapy* / Q000821:virology; D016031:Liver Transplantation; D008495:Medical Oncology / Q000191:economics / Q000592:standards; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011314:Preventive Health Services / Q000191:economics; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D017325:Hepatitis B Vaccines